Search
BioCardia Inc
BCDAAdd to Watchlist
0.861USD
-0.065-7.02%
Close 10-30 16:00（ET）
13.04MMarket Cap
LossP/E TTM
BioCardia Inc (BCDA) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to BioCardia Inc in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
15.500USD+1536.06%
BCDA Analyst Recommendation Trends
In the current month, BCDA has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BCDA average Analyst price target in the last month is 15.500.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
BCDA Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
Financial Forecasting
Based on analysts' estimates, BCDA EPS is projected to reach -0.130 in FY2026Q3, following reported EPS of -0.133 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.17
-0.17
-0.18
-0.13
-0.16
Actual
-0.19
-0.21
-0.13
--
--
Surprise
-9.31%
-26.62%
+25.90%
--
--
FAQs
What is BioCardia Inc's price target?
Analysts forecast that BioCardia Inc's price target is USD 15.50, with the highest forecast at USD 25.00 and the lowest forecast at USD 6.00.
How have BioCardia IncBCDA's recent earnings per share performed?
The market expectation was USD -0.13, while BioCardia IncBCDA's earnings per share (EPS) for the previous quarter was USD -0.21. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for BioCardia Inc?
Based on the ratings of BioCardia Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.